Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 147-150, 2008.
Artigo
em Chinês
| WPRIM
| ID: wpr-348147
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of an adjuvant chemotherapy regimen XELOX (Capecitabine puls Oxaliplatin) used after curative resection for stage III colorectal cancer.</p><p><b>METHODS</b>From Jan. 1998 to Jan. 2004, 256 cases with stage III colorectal cancer randomized received de Gramont, modified FOLFOX4 (mFOLFOX4) and XELOX regimens. The 3-year disease-free survival (DFS) and overall survival (OS) were compared within the three groups and relative prognosis factors within mFOLFOX4 and XELOX groups. Therapeutic adverse events were recorded and analyzed with Kaplan-Meier test.</p><p><b>RESULTS</b>98, 87 and 71 cases were respectively enrolled in the de Gramont, mFOLFOX4 and XELOX groups, mFOLFOX4 and XELOX had superior efficacy compared with de Gramont regimen. The two former could significantly improve 3-year DFS (79.7% vs. 66.2%, P = 0.015; 81.5% vs. 66.2%, P = 0.004) and medium survival time (40.2 mon vs. 37.8 mon, P = 0.024; 41.4 mon vs. 37.8 mon, P = 0.014). Meanwhile they could respectively decrease the ratio of recurrence risk by 18.0% (P = 0.024) and 21.0% (P = 0.003). The relative benefit of mFOLFOX4 versus XELOX didn't differ for 3-year DFS [hazard ratio (HR) 0.84, 95% confidence interval (CI) 0.79-1.12, P = 0.13] and OS (HR 0.87, 95% CI 0.84-1.06, P = 0.54). In the analysis of DFS in relative prognosis factors, XELOX had a better trend of survival advantage. mFOLFOX4 had higher adverse events within these regimens, especially in grade 3 or 4 neutropenia and peripheral neurologic adverse events.</p><p><b>CONCLUSION</b>XELOX maintains its efficacy and safety ratio in advanced colorectal cancer. Patients have good tolerance and compliance. The regiment is deserves to be applied in clinical treatment. Oxaliplatin;</p>
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Compostos Organoplatínicos
/
Patologia
/
Neoplasias Retais
/
Cirurgia Geral
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Modelos de Riscos Proporcionais
/
Leucovorina
/
Taxa de Sobrevida
/
Estudos Retrospectivos
/
Seguimentos
Tipo de estudo:
Estudo observacional
/
Estudo prognóstico
/
Fatores de risco
Limite:
Adulto
/
Idoso
/
Feminino
/
Humanos
/
Masculino
Idioma:
Chinês
Revista:
Chinese Journal of Oncology
Ano de publicação:
2008
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS